All In Biotech

Drug Trial Radar · NCT07300085

A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)

A Phase 1, Double-blind, Randomized Trial to Evaluate Safety and Immunogenicity of Fluzone® High-Dose Influenza Vaccine When Concomitantly Administered With CD388, a Novel Long-Acting Antiviral Conjugate for the Prevention of Influenza

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 710 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

710

Planned (sponsor's estimate)

Start

Nov 8, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Dec 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza is currently recommended. However, the real-world vaccine effectiveness varied from 10% to 60% in the general population across the years of 2004 to 2024, with effectiveness in most years below 50% (CDC 2025) and decreasing to as low as 5% in immunocompromised individuals (Hughes 2021). Researchers are looking for other ways to prevent severe illness from the influenza virus. The goals of this study are to learn if: * MK-1406 (formerly CD388) is safe to take with Fluzone® * MK-1406 affects the immune response to Fluzone®

Conditions

  • Healthy Participants

Interventions

  • Fluzone® High-Dose (HD) influenza vaccineBiological

    Fluzone® HD injectable suspension administered by intramuscular (IM) injection

  • MK-1406 InjectionCombination product

    MK-1406 liquid for injection administered subcutaneously

  • PlaceboCombination product

    MK-1406 matched liquid for SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean of Hemagglutinin Inhibition (HAI) Titers Against the Influenza Strains Contained in the Vaccine Among Participants Receiving Concomitant Fluzone® High-Dose (HD) and MK-1406 Compared to Participants Who Receive Fluzone® HD and PlaceboTime frame: Predose (Day 1), Day 15 and Day 29
  2. Percentage of Participants with Seroconversion Rates against the Influenza Strains Contained in the Vaccine Among Participants Receiving Concomitant Fluzone® HD and MK-1406 Compared to Participants Who Receive Fluzone® HD and PlaceboTime frame: Predose (Day 1), Day 15 and Day 29

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Foothills Research Center ( Site 0010)

    Phoenix, Arizona · Recruiting

  • Parexel ( Site 0001)

    Glendale, California · Recruiting

  • Flourish Research ( Site 0014)

    Miami, Florida · Recruiting

  • South Florida Research Center, Inc ( Site 0009)

    Miami, Florida · Recruiting

  • DelRicht Research ( Site 0005)

    New Orleans, Louisiana · Recruiting

  • Parexel ( Site 0002)

    Baltimore, Maryland · Recruiting

  • DelRicht Research ( Site 0012)

    Gulfport, Mississippi · Recruiting

  • Drug Trials America ( Site 0006)

    Hartsdale, New York · Recruiting

  • Rochester Clinical Research, Inc. ( Site 0008)

    Rochester, New York · Recruiting

  • DelRicht Research ( Site 0015)

    Charlotte, North Carolina · Recruiting

  • Tekton Research, LLC. ( Site 0007)

    Oklahoma City, Oklahoma · Recruiting

  • Epic Clinical Research ( Site 0003)

    Lewisville, Texas · Recruiting

  • Elevate Clinical Research - McAllen ( Site 0013)

    McAllen, Texas · Recruiting

  • Clinical Trials of Texas, LLC-Clinical Research ( Site 0004)

    San Antonio, Texas · Recruiting

  • Texas Health Care ( Site 0011)

    Stephenville, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.